Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2014

01-06-2014 | Research Article

TRIM31 is downregulated in non-small cell lung cancer and serves as a potential tumor suppressor

Authors: Hui Li, Yi Zhang, Yue Zhang, Xue Bai, Yang Peng, Ping He

Published in: Tumor Biology | Issue 6/2014

Login to get access

Abstract

The present study aims to investigate expression pattern and biological roles of TRIM31 in human non-small cell lung cancer (NSCLC). We examined TRIM31 expression in 116 NSCLC tissues and 20 corresponding normal lung tissues by immumohistochemistry. We found TRIM31 downregulation in 47 out of 116 (40.5 %) cancer samples, which correlated with tumor status (p = 0.0132), advanced p-TNM stage (p = 0.001), and nodal metastasis (p = 0.0382). TRIM31 expression was lower in lung cancer cell lines than normal bronchial cell line HBE. Transfection of TRIM31 plasmid was performed in H157 and H1299 cells. TRIM31 overexpression inhibited cell growth rate and colony formation ability in both cell lines. In addition, expression of cell cycle regulator cyclin D1 and cyclin E were decreased after TRIM31 transfection. In conclusion, TRIM31 might serve as a tumor suppressor in non-small cell lung cancer.
Literature
1.
2.
Li H, Wang RM, Liu SG, Zhang JP, Luo JY, Zhang BJ, et al. Abnormal expression of FLOT1 correlates with tumor progression and poor survival in patients with non-small cell lung cancer. Tumour Biol. 2013. doi:10.​1007/​s13277-013-1434-3.
3.
Wang L, Meng L, Wang XW, Ma GY, Chen JH. Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol. 2013. doi:10.​1007/​s13277-013-1255-4.
4.
Dong QZ, Wang Y, Dong XJ, Li ZX, et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. 2011;18:857–65.CrossRefPubMed
5.
Dong QZ, Wang Y, Tang ZP, Fu L, et al. Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. Am J Pathol. 2013;182:954–64.CrossRefPubMed
6.
Dong QZ, Zhao Y, Liu Y, Wang Y, et al. Overexpression of SCC-S2 correlates with lymph node metastasis and poor prognosis in patients with non-small-cell lung cancer. Cancer Sci. 2010;101:1562–9.CrossRefPubMed
7.
Sugiura T, Miyamoto K. Characterization of TRIM31, upregulated in gastric adenocarcinoma, as a novel RBCC protein. J Cell Biochem. 2008;105:1081–91.CrossRefPubMed
8.
Watanabe M, Tsukiyama T, Hatakeyama S. TRIM31 interacts with p52(Shc) and inhibits Src-induced anchorage-independent growth. Biochem Biophys Res Commun. 2009;388:422–7.CrossRefPubMed
9.
Zhang M, Luo W, Huang B, Liu Z, et al. Overexpression of JAM-A in non-small cell lung cancer correlates with tumor progression. PLoS One. 2013;8:e79173.PubMedCentralCrossRefPubMed
10.
Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994;79:573–82.CrossRefPubMed
11.
Vizkeleti L, Ecsedi S, Rakosy Z, Orosz A, et al. The role of CCND1 alterations during the progression of cutaneous malignant melanoma. Tumour Biol. 2012;33:2189–99.CrossRefPubMed
12.
Liu Y, Wang L, Lin XY, Wang J, et al. The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells. Tumour Biol. 2013;34:1641–50.CrossRefPubMed
13.
Liu J, Liao Q, Zhang Y, Sun S, Zhong C, Liu X. Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis. Tumour Biol. 2012;33(5):1467–76. doi:10.​1007/​s13277-012-0397-0.
14.
Musgrove EA, Caldon CE, Barraclough J, Stone A, et al. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558–72.CrossRefPubMed
15.
16.
Donnellan R, Chetty R. Cyclin E in human cancers. FASEB J. 1999;13:773–80.PubMed
17.
18.
Huang LN, Wang DS, Chen YQ, Li W, et al. Meta-analysis for cyclin E in lung cancer survival. Clin Chim Acta. 2012;413:663–8.CrossRefPubMed
19.
Zhang LQ, Jiang F, Xu L, Wang J, et al. The role of cyclin D1 expression and patient’s survival in non-small-cell lung cancer: a systematic review with meta-analysis. Clin Lung Cancer. 2012;13:188–95.CrossRefPubMed
20.
21.
Patrussi L, Savino MT, Pellegrini M, Paccani SR, et al. Cooperation and selectivity of the two Grb2 binding sites of p52Shc in T-cell antigen receptor signaling to Ras family GTPases and Myc-dependent survival. Oncogene. 2005;24:2218–28.CrossRefPubMed
22.
Peeper DS, Upton TM, Ladha MH, Neuman E, et al. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature. 1997;386:177–81.CrossRefPubMed
Metadata
Title
TRIM31 is downregulated in non-small cell lung cancer and serves as a potential tumor suppressor
Authors
Hui Li
Yi Zhang
Yue Zhang
Xue Bai
Yang Peng
Ping He
Publication date
01-06-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1763-x

Other articles of this Issue 6/2014

Tumor Biology 6/2014 Go to the issue

Research Article

The combined use of serum neurotensin and IL-8 as screening markers for colorectal cancer

Research Article

XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis

Research Article

miR-22 targets the 3′ UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy

Research Article

Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy

Research Article

Cyclin D1 G870A polymorphism and the risk of hepatocellular carcinoma in a Chinese population

Research Article

APE1 Asp148Glu polymorphism and lung cancer susceptibility
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits